All lobbying filings

TIBER CREEK GROUP

TIBER CREEK GROUP filed a Q2 report for VERTEX PHARMACEUTICALS on July 18, 2026, reporting $60,000 in lobbying income.

Lobbying for VERTEX PHARMACEUTICALS · Global biotechnology company.

All filings by TIBER CREEK GROUP · Everything VERTEX PHARMACEUTICALS has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 18, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.

Defense

Issues related to coverage of opioid alternatives.

Bills named in this filing 3

H.R. 1227
Alternatives to PAIN Act
S. 475
Alternatives to PAIN Act
H.R. 1518
New Era of Preventing End-Stage Kidney Disease Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.